Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more
Diffusion Pharmaceuticals

Improving Oxygen Availability
to Vital Organs

A Treatment for Life-Threatening Conditions Related to Hypoxia

Novel Mechanism of Action

Lead drug trans sodium crocetinate (TSC) enhances the availability of oxygen by improving diffusion through the blood.

Selective for Hypoxic Tissue

TSC’s mechanism of action enhances oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Attractive Safety Profile

TSC has been safe and well tolerated in completed preclinical and clinical studies.

OUR PIPELINE

Potential treatment
of COVID-19

Diffusion Pharmaceuticals is actively evaluating trans sodium crocetinate (TSC)’s potential to improve the availability of oxygen in patients with COVID-19, building upon data from prior clinical studies in peripheral artery disease and glioblastoma multiform (GBM) brain cancer.

Learn more

Scientific Publications

Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. Brain Research. 2010; 1309:136-145.

Protection against focal ischemic injury to the brain by trans-sodium crocetinate. J Neurosurg. 2010; 113:802-809.

Metabolic reflow as a therapy for ischemic brain injury. H. Feng et al. (eds.), Early Brain Injury or Cerebral Vasospasm, Acta Neurochirurgica Supplementum, Vol. 110/2, DOI 10.1007/978-3-7091-0356-2_16, # Springer-Verlag/Wien 2011.

Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke. Brain Research. 2014; 1583:245-254.

Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. J Neurosurf. 2016: JNS515-2693

Trans sodium crocetinate: functional neuroimaging studies in a hypoxic brain tumor: Laboratory investigation. J Neurosurg. 2011; 115:749-753.

Effect of trans sodium crocetinate on brain tumor oxygenation: Laboratory investigation. J Neurosurg. 2009; 111:226–229.

Trans sodium crocetinate sensitizes glioblastoma multiforme tumors to radiation. J Neurosurg. 2008; 108:972-978.

Trans-sodium crocetinate for treating hypoxia/ischemia. Expert Opinion on Investigational Drugs. 2008; 17:917-24.

News

The latest news, press releases, and more.

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

 Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

 Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

 Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”),…

Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial

 Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial 2560 1707 Diffusion Pharmaceuticals Inc.

Twenty-four patient Phase 1b safety and tolerability study initiated in Romania CHARLOTTESVILLE, Va., Sept. 10,…

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

 Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”),…

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors

 Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors 2560 1707 Diffusion Pharmaceuticals Inc.

Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial CHARLOTTESVILLE, Va., Sept. 01,…

Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

Continues global clinical development of TSC for the treatment of COVID-19 CHARLOTTESVILLE, Va., Aug. 10,…

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

 Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC 2560 1707 Diffusion Pharmaceuticals Inc.

Guidance being incorporated into global study protocol Enrollment of first patient now expected in August…

Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc

 Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc 2560 1707 Diffusion Pharmaceuticals Inc.

Phase 1b dosing expected to begin this month Data read-out expected later this quarter CHARLOTTESVILLE,…

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients

 Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected…

Back to top